Although many previous network meta-analyses analyzed some preferable choices for EGFR-mutated advanced NSCLC based on different mutation statuses via indirect comparisons [14], some important data were still unavailable, such as final overall survival (OS) for FLAURA and NEJ026 study and PFS for CTONG-1509, RELAY, and ACTIVE study [7, 8, 15–18]. Here, EGFR is linked to non-small cell lung carcinoma.